U.S. MarketsSeptember 30 at 02:44 PM

Bristol-Myers Squibb (BMY) discloses fatal liver injury in phase 3 fibrosis programme

StockNow breaking-news AI analysis

The retrieved report describes closer liver monitoring in Bristol Myers Squibb’s Phase 3 Aloft extension after liver injuries and a fatal event, while noting uncertainty about treatment exposure and causation.

1 stocks

BMYBristol-Myers Squibb Co.$62.77Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

Geopolitics

US President Trump says you will see things happening very soon (regarding Iran); there has been historic flows of oil out of Hormuz in the last three days

Fed

Fed's Cook (voter) says inflation has been too high for too long and she is committed to returning inflation to 2% while preserving labour market strength

Commodities